Simplex Trading’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $941K | Buy |
7,144
+1,307
| +22% | +$173K | ﹤0.01% | 2563 |
|
|
2025
Q4 | $828K | Buy |
5,837
+2,939
| +101% | +$426K | ﹤0.01% | 2814 |
|
|
2025
Q3 | $406K | Sell |
2,898
-945
| -25% | -$128K | ﹤0.01% | 4087 |
|
|
2025
Q2 | $483K | Buy |
3,843
+1,443
| +60% | +$165K | ﹤0.01% | 3545 |
|
|
2025
Q1 | $265K | Buy |
+2,400
| New | +$304K | ﹤0.01% | 4044 |
|
|
2024
Q3 | – | Sell |
-9,648
| Closed | -$1.32M | – | 9191 |
|
|
2024
Q2 | $1.33M | Buy |
+9,648
| New | +$1.32M | ﹤0.01% | 2617 |
|
|
2022
Q4 | – | Sell |
-3,318
| Closed | -$389K | – | 9965 |
|
|
2022
Q3 | $352K | Sell |
3,318
-10,785
| -76% | -$1.09M | ﹤0.01% | 3882 |
|
|
2022
Q2 | $1.37M | Sell |
14,103
-9,456
| -40% | -$873K | ﹤0.01% | 2262 |
|
|
2022
Q1 | $2.21M | Buy |
+23,559
| New | +$2M | ﹤0.01% | 2014 |
|
|
2021
Q4 | – | Sell |
-5,409
| Closed | -$498K | – | 11080 |
|
|
2021
Q3 | $527K | Sell |
5,409
-800
| -13% | -$75.6K | ﹤0.01% | 4034 |
|
|
2021
Q2 | $604K | Buy |
+6,209
| New | +$595K | ﹤0.01% | 3869 |
|
|
2021
Q1 | – | Sell |
-1,162
| Closed | -$122K | – | 9612 |
|
|
2020
Q4 | $111K | Sell |
1,162
-5,529
| -83% | -$534K | ﹤0.01% | 5350 |
|
|
2020
Q3 | $643K | Buy |
6,691
+6,690
| +669,000% | +$774K | ﹤0.01% | 2730 |
|
|
2020
Q2 | $0 | Buy |
+1
| New | +$111 | ﹤0.01% | 8078 |
|
|
2019
Q4 | – | Sell |
-13,502
| Closed | -$1.41M | – | 7726 |
|
|
2019
Q3 | $1.22M | Buy |
13,502
+5,176
| +62% | +$484K | ﹤0.01% | 1758 |
|
|
2019
Q2 | $702K | Buy |
8,326
+1,103
| +15% | +$90.6K | ﹤0.01% | 2255 |
|
|
2019
Q1 | $636K | Buy |
+7,223
| New | +$604K | ﹤0.01% | 2410 |
|
|
2018
Q4 | – | Sell |
-6,853
| Closed | -$657K | – | 7533 |
|
|
2018
Q3 | $842K | Sell |
6,853
-2,216
| -24% | -$251K | ﹤0.01% | 2067 |
|
|
2018
Q2 | $890K | Buy |
9,069
+8,869
| +4,435% | +$794K | ﹤0.01% | 1904 |
|
|
2018
Q1 | $16K | Buy |
+200
| New | +$16.9K | ﹤0.01% | 3569 |
|
|
2017
Q4 | – | Sell |
-1,076
| Closed | -$73.4K | – | 6423 |
|
|
2017
Q3 | $65K | Buy |
1,076
+855
| +387% | +$45.1K | ﹤0.01% | 2045 |
|
|
2017
Q2 | $10K | Buy |
+221
| New | +$10.7K | ﹤0.01% | 3976 |
|
|
2017
Q1 | – | Sell |
-3,618
| Closed | -$155K | – | 6556 |
|
|
2016
Q4 | $140K | Buy |
+3,618
| New | +$164K | 0.01% | 1288 |
|
|
2016
Q2 | – | Sell |
-5,408
| Closed | -$249K | – | 6228 |
|
|
2016
Q1 | $213K | Buy |
+5,408
| New | +$215K | 0.02% | 845 |
|
|
2015
Q3 | – | Sell |
-625
| Closed | -$30.2K | – | 5950 |
|
|
2015
Q2 | $29K | Buy |
+625
| New | +$26.5K | ﹤0.01% | 2132 |
|
|
2015
Q1 | – | Sell |
-10,573
| Closed | -$378K | – | 5368 |
|
|
2014
Q4 | $236K | Buy |
+10,573
| New | +$200K | 0.03% | 529 |
|
Other funds holding NBIX
VPM
VCM
Simplex Trading's NBIX Position: Q1 2026 in Review
Simplex Trading increased its Neurocrine Biosciences (NBIX) stake by 22% in Q1 2026, buying an estimated $173K and bringing the position to 7,144 shares worth $941K. The position accounts for ﹤0.01% of the portfolio, ranked #2563.
Simplex Trading first reported a position in NBIX in Q4 2014 and has held it in 26 quarters since. The position peaked at $2.21M in Q1 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Simplex Trading held 7,144 shares of Neurocrine Biosciences worth $941K as of Q1 2026.
- Simplex Trading bought 1,307 Neurocrine Biosciences shares in Q1 2026, an estimated $173K.
- Neurocrine Biosciences made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #2563 holding.
- Simplex Trading first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 26 quarters since.
- Simplex Trading's Neurocrine Biosciences position peaked at $2.21M in Q1 2022.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.